Better Health · Better You
We are pioneering cutting edge stem cell technology
to translate research into transformative medicines
As an innovative biopharmaceutical company,
we aspire to improve patients' treatment outcomes
and quality of life, targeting areas in autoimmune,
degenerative, and rare diseases.
T-MSC is based on ImStem’s patented technology,
which can differentiate human embryonic stem
cells (hESCs) into mesenchymal stem cells (MSCs)
with high efficiency, consistency, and quality,
through a trophoblast-like intermediate stage.
The MSC derived with this proprietary technology
is called T-MSC.
Currently the clinical trial to study the proprietary T-MSC (IMS001) cell therapy in patients with multiple sclerosis is under way. IMS001 is a human embryonic cell (hESC) derived mesenchymal stem cell (MSC) investigational drug.
A clinical trial to study the proprietary T-MSC (IMS001) cell therapy in patients with multiple sclerosis is ongoing. IMS001 is a human embryonic (hESC) derived mesenchymal stem cell (MSC). The Phase 1/2a study is enrolling multiple sclerosis patients who meet the following criteria: